KR101549296B1 - 고역가 고순도 바이러스 스톡의 생산 방법 및 이의 사용 방법 - Google Patents

고역가 고순도 바이러스 스톡의 생산 방법 및 이의 사용 방법 Download PDF

Info

Publication number
KR101549296B1
KR101549296B1 KR1020127029690A KR20127029690A KR101549296B1 KR 101549296 B1 KR101549296 B1 KR 101549296B1 KR 1020127029690 A KR1020127029690 A KR 1020127029690A KR 20127029690 A KR20127029690 A KR 20127029690A KR 101549296 B1 KR101549296 B1 KR 101549296B1
Authority
KR
South Korea
Prior art keywords
virus
tcid
sample
delete delete
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127029690A
Other languages
English (en)
Korean (ko)
Other versions
KR20130020954A (ko
Inventor
다몬 알. 아셔
아만다 비. 카츠
나비드 제트. 칸
우쉬마 메타
Original Assignee
이엠디 밀리포어 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101549296(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 이엠디 밀리포어 코포레이션 filed Critical 이엠디 밀리포어 코포레이션
Publication of KR20130020954A publication Critical patent/KR20130020954A/ko
Application granted granted Critical
Publication of KR101549296B1 publication Critical patent/KR101549296B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020127029690A 2010-04-14 2011-04-08 고역가 고순도 바이러스 스톡의 생산 방법 및 이의 사용 방법 Expired - Fee Related KR101549296B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32422010P 2010-04-14 2010-04-14
US61/324,220 2010-04-14
PCT/US2011/031747 WO2011130119A2 (en) 2010-04-14 2011-04-08 Methods of producing high titer, high purity virus stocks and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20130020954A KR20130020954A (ko) 2013-03-04
KR101549296B1 true KR101549296B1 (ko) 2015-09-01

Family

ID=44148425

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127029690A Expired - Fee Related KR101549296B1 (ko) 2010-04-14 2011-04-08 고역가 고순도 바이러스 스톡의 생산 방법 및 이의 사용 방법

Country Status (9)

Country Link
US (1) US9644187B2 (enExample)
EP (1) EP2377927B1 (enExample)
JP (3) JP2013523175A (enExample)
KR (1) KR101549296B1 (enExample)
CN (1) CN102985536B (enExample)
BR (1) BR112012026095A2 (enExample)
ES (1) ES2736166T3 (enExample)
SG (1) SG184833A1 (enExample)
WO (1) WO2011130119A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
CN104160019A (zh) * 2012-03-13 2014-11-19 Emd密理博公司 使用离心辅助的感染以增加病毒滴度
CN104812893B (zh) * 2012-11-22 2018-08-03 旭化成医疗株式会社 高感染滴度的细小病毒的生产方法
EP2958995A4 (en) * 2013-02-22 2016-11-23 Agency Science Tech & Res CHROMATOGRAPHIC CLEANING OF VIRUS PREPARATIONS WITH NEGATIVELY LOADED PARTICLES
DK3044339T3 (da) 2013-09-10 2019-08-12 MockV Solutions Fremgangsmåder og sæt til kvantificering af fjernelsen af falske (MOCK) viruspartikler fra en renset opløsning
RU2701948C1 (ru) * 2015-11-06 2019-10-02 Асахи Касеи Медикал Ко., Лтд. Способ получения парвовируса, характеризующегося высоким титром инфекционности и высокой чистотой
DE102016005049B4 (de) 2016-04-26 2020-06-18 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung des logarithmischen Reduktionswertes LRV eines Größenausschlussfilters
EP3299454A1 (en) * 2016-09-21 2018-03-28 Deutsches Krebsforschungszentrum Optimized method for large scale production of parvovirus h-1 in an essentially serum-free medium
EP3141611A3 (en) 2016-10-21 2017-05-10 Bayer Healthcare LLC Validation of continuous viral clearance
US10961512B2 (en) * 2017-04-17 2021-03-30 Dao-Yao He Compositions and kits for purification of viral particles from host cells
KR102453351B1 (ko) * 2017-07-05 2022-10-07 에스케이바이오사이언스(주) 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법
EP3446710A1 (en) * 2017-08-25 2019-02-27 Glenmark Pharmaceuticals S.A. Methods of inactivating viral contaminants
CN108841794B (zh) * 2018-06-08 2021-11-30 苏州良辰生物医药科技有限公司 一种病毒原液的制备方法
JP7588466B2 (ja) * 2020-01-22 2024-11-22 旭化成メディカル株式会社 パルボウイルスの生産方法
JP7390466B2 (ja) * 2020-02-28 2023-12-01 旭化成メディカル株式会社 ウイルスクリアランス性能の評価方法
US12403428B2 (en) 2020-06-24 2025-09-02 Asahi Kasei Life Science Corporation Evaluation method for protein-containing solution
CA3195893A1 (en) * 2020-09-21 2022-03-24 Bayer Healthcare Llc Pathogen clearance system and method
US12203914B2 (en) 2020-11-12 2025-01-21 Sartorius Bioanalytical Instruments, Inc. Viral clearance evaluation for biological medical product preparation processes
EP4317460A4 (en) 2021-03-26 2024-10-23 Asahi Kasei Medical Co., Ltd. Viral clearance test method
WO2022252098A1 (zh) * 2021-05-31 2022-12-08 中国科学院深圳先进技术研究院 噬菌体制剂的制备方法、药物组合物以及应用
JP7665143B2 (ja) * 2021-06-24 2025-04-21 株式会社島津製作所 ウイルス試料の濃縮方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127264A2 (en) * 2006-04-28 2007-11-08 The Trustees Of The University Of Pennsylvania Scalable production method for aav
WO2008026225A2 (en) * 2006-09-01 2008-03-06 Bharat Biotech International Limited A vaccine for chikungunya virus infection

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622663A (en) 1968-06-13 1971-11-23 American Home Prod Purification of viruses on treated calcium dihydrogen orthophosphate monohydrate adsorbent
US3919044A (en) 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
SU579309A1 (ru) 1973-11-16 1977-11-05 Ленинградский Политехнический Институт Им.М.И.Калинина Способ получени вакцины
FR2475572A1 (fr) 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
JPS6147186A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147185A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
US6265149B1 (en) 1986-01-22 2001-07-24 Institut Pasteur In vitro diagnostic methods and kits for the detection of HIV-2-specific antibodies
US5824482A (en) 1986-06-23 1998-10-20 Institut Pasteur Purification, cloning, and characterization of a novel human immunodeficiency virus LAVMAL
US4814268A (en) 1986-10-06 1989-03-21 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US4859597A (en) * 1987-07-27 1989-08-22 Igene Biotechnology, Inc. Production of phage and phage-associated lysin
NZ225583A (en) 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5268292A (en) 1988-06-27 1993-12-07 Robertson Betty H Reproducible generation of high yields of hepatitis A virus by cell culture
GB8914968D0 (en) 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US5719051A (en) 1989-12-22 1998-02-17 Immuno Aktiengesellschaft Perfusion system and a method for the large scale production of virus or virus antigen
DE4003543A1 (de) 1990-02-06 1991-08-08 Orpegen Med Molekularbioforsch Verfahren zur abreicherung von viren in loesungen und zur bestimmung der abreicherungsrate von viren
US6709811B1 (en) 1990-05-24 2004-03-23 The United States Of America As Represented By The Department Of Health And Human Services Versatile reagent for detecting murine leukemia viruses
DE69009066T3 (de) 1990-06-15 2001-07-19 Innogenetics N.V., Gent SIV cpz-ant Retrovirus und seine Anwendungen.
IT1248075B (it) 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5658779A (en) 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
ES2126620T5 (es) 1992-10-06 2010-05-21 Siemens Healthcare Diagnostics Products Gmbh Retrovirus del grupo de los vih y su utilizacion.
WO1995025789A1 (en) 1994-03-22 1995-09-28 The Immune Response Corporation Highly efficient production and isolation of viral particles
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
US5756341A (en) 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
AU1733697A (en) 1996-02-29 1997-09-16 Takara Shuzo Co., Ltd. Method of purifying and removing viruses
BR9708401A (pt) 1996-03-29 2000-01-04 Univ Otago Vetores de vìrus de para-varìola
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
AU732703B2 (en) 1996-11-20 2001-04-26 Crucell Holland B.V. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
ZA982950B (en) 1997-04-08 1998-10-19 Merck & Co Inc Stabilized human papillomavirus formulations
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
US6037456A (en) 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
US5994134A (en) 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
PL347472A1 (en) 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
WO2000011149A1 (en) 1998-08-24 2000-03-02 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
CN1087032C (zh) * 1998-12-14 2002-07-03 彭朝晖 一种生产重组腺病毒的方法
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
CA2356373A1 (fr) * 1998-12-31 2000-07-13 Aventis Pharma S.A. Methode de separation de particules virales
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
US6316185B1 (en) 1999-09-29 2001-11-13 Mountain View Pharmaceuticals, Inc. Quantitation of viruses by light scattering
AU1811301A (en) 1999-12-02 2001-06-12 General Hospital Corporation, The Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
CA2395820A1 (en) 1999-12-29 2001-07-05 Genzyme Corporation Method using filtration aids for the separation of virus vectors from nucleic acids and other cellular contaminants
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
WO2002018550A1 (en) 2000-08-25 2002-03-07 The General Hospital Corporation Selective precipitation of viruses
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
US20050118701A1 (en) 2002-03-29 2005-06-02 Weichang Zhou Large scale methods of producing adenovirus and adenovirus seed stocks
WO2003085138A1 (en) 2002-03-29 2003-10-16 Merck & Co., Inc. Methods of virus production
ATE427990T1 (de) 2002-04-30 2009-04-15 Oncolytics Biotech Inc Verbesserte reinigungsmethode fur viren
WO2003097797A2 (en) 2002-05-14 2003-11-27 Merck & Co., Inc. Methods of adenovirus purification
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US20040033585A1 (en) 2002-06-07 2004-02-19 Mccormick Alison A. Flexible vaccine assembly and vaccine delivery platform
AU2003279240A1 (en) 2002-06-21 2004-01-06 Genetix Pharmaceuticals, Inc. Methods for purifying viral particles for gene therapy
CA2491805A1 (en) * 2002-07-10 2004-01-22 Transgene S.A. Modified adenoviral fiber with ablated binding to cellular receptors
UA85543C2 (ru) 2002-09-05 2009-02-10 Бавариан Нордик А/С Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
US20050009168A1 (en) 2003-05-12 2005-01-13 Robbins Joan Marie Methods and apparatus for Adeno associated virus purification
AU2004249199B2 (en) 2003-06-18 2008-07-24 Onyx Pharmaceuticals, Inc. Method for purifying virus
AU2003272868A1 (en) 2003-10-15 2005-04-27 Agtc Gene Technology Company Ltd. Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors
US20050153419A1 (en) 2003-12-23 2005-07-14 Schering Corporation Methods for producing cell lines stable in serum-free medium suspension culture
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
EP4170024A1 (en) 2004-06-01 2023-04-26 Genzyme Corporation Compositions and methods to prevent aav vector aggregation
DE102004049290A1 (de) 2004-10-09 2006-04-20 Bayer Healthcare Ag Verfahren zur Herstellung von Virusmaterial
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CA2586107A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. A novel method for the production and purification of adenoviral vectors
US20060281075A1 (en) 2004-12-22 2006-12-14 Large Scale Biology Corporation Purification of viruses, proteins and nucleic acids
US7344839B2 (en) 2004-12-23 2008-03-18 Aurx, Inc. Virus preparations and methods
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
DE102005047301B4 (de) 2005-09-30 2009-04-16 Sartorius Stedim Biotech Gmbh Verfahren zum Nachweis der Virenabreicherung für die Validierung von Filtern und Filtrationsprozessen
WO2007059473A2 (en) 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
US7754421B2 (en) 2005-11-18 2010-07-13 National Research Council Of Canada Detection of intact recombinant viruses
KR101157176B1 (ko) 2005-12-20 2012-06-20 삼성전자주식회사 세포 또는 바이러스의 농축 또는 정제용 미세유동장치 및방법
US7851196B2 (en) 2006-05-01 2010-12-14 The Regents Of The University Of California Methods for purifying adeno-associated virus particles
CA2671869A1 (en) 2006-12-15 2008-06-26 Schering-Plough Ltd. Method for replicating influenza virus in culture
WO2008109721A1 (en) * 2007-03-06 2008-09-12 Introgen Therapeutics, Inc. Chromatographic methods for assessing adenovirus purity
KR20170001720A (ko) * 2007-03-14 2017-01-04 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
CA2685497A1 (en) 2007-03-27 2008-10-02 University Of Maryland, College Park Imprinted polymeric materials for binding various targets such as viruses
KR101744430B1 (ko) 2007-05-04 2017-06-20 백스터 인터내셔널 인코포레이티드 바이러스 정제를 위한 연속 초원심분리용 당 용액의 제조
JP2011511640A (ja) * 2008-02-12 2011-04-14 サノフィ パストゥール リミテッド ポックス・ウイルスの精製方法
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
US9651469B1 (en) * 2016-01-27 2017-05-16 General Electric Company Electrostatic particle sensor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127264A2 (en) * 2006-04-28 2007-11-08 The Trustees Of The University Of Pennsylvania Scalable production method for aav
WO2008026225A2 (en) * 2006-09-01 2008-03-06 Bharat Biotech International Limited A vaccine for chikungunya virus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bio/Technology. 1993, vol. 11, pages 173-178.
BioProcess International. 2005, vol. 3, no. 10, Supplement, pages 39-43.*

Also Published As

Publication number Publication date
JP6522054B2 (ja) 2019-05-29
US20120088228A1 (en) 2012-04-12
JP2013523175A (ja) 2013-06-17
SG184833A1 (en) 2012-11-29
JP2015126757A (ja) 2015-07-09
CN102985536B (zh) 2017-12-05
US9644187B2 (en) 2017-05-09
WO2011130119A3 (en) 2012-03-29
KR20130020954A (ko) 2013-03-04
WO2011130119A8 (en) 2011-12-29
EP2377927A1 (en) 2011-10-19
CN102985536A (zh) 2013-03-20
BR112012026095A2 (pt) 2015-09-15
JP6284500B2 (ja) 2018-02-28
ES2736166T3 (es) 2019-12-26
EP2377927B1 (en) 2019-05-22
WO2011130119A2 (en) 2011-10-20
JP2017195897A (ja) 2017-11-02

Similar Documents

Publication Publication Date Title
KR101549296B1 (ko) 고역가 고순도 바이러스 스톡의 생산 방법 및 이의 사용 방법
US7625570B1 (en) Methods for purifying adeno-associated virus
JP6956824B2 (ja) 生体高分子ユニットおよびウイルスを液体から分離するための方法
US7851196B2 (en) Methods for purifying adeno-associated virus particles
JP2019083822A (ja) 組換えａａｖベクターの改良された精製方法
JP5711369B2 (ja) 蛋白製剤の製造方法
CN106574252B (zh) 从细胞培养物中纯化脊髓灰质炎病毒的方法
KR20170138462A (ko) 바이러스에 대한 무균 정제 방법
CN103468653B (zh) 一种肠道病毒71型的纯化方法
CN113302197A (zh) 包括使用活性炭材料的工序的纯化抗体的方法
CN109563488B (zh) 夹杂猪环状病毒的溶液的处理方法
KR100900013B1 (ko) 유체로부터 재조합 인간 에리스로포이에틴을 정제하는 방법
CN120843734A (zh) 病毒清除性能的确定方法
US20230212530A1 (en) Virus purification method using apatite column
KR100451308B1 (ko) 단백질 의약품 정제 방법에서의 바이러스 제거 방법
CN116855461A (zh) 一种呼肠孤病毒3型的纯化方法及应用
Shoaebargh et al. Developing and Optimizing Monolithic Column Chromatography Purification Process for Oncolytic Rhabdoviral Vectors
SG188947A1 (en) Method for reducing dna impurities in viral compositions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220827

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220827